摘要
背景:由于病原菌对抗生素的耐药性增加,因此需要有效和安全的药物.一种替代抗生素的方法是脂肽,它是作为二次代谢物产生的。由许多微生物组成。它们具有广谱的抗病原体活性和抗癌特性。在微生物产生的各种脂肽中,达普霉素、表面素和多粘菌素作为一种药物得到了广泛的应用,但其作用机制还没有得到很好的描述。在硅类药物中,这些脂肽的设计由于其复杂的结构而成为一个挑战。为了启动生理反应,必须识别其受体(脂肽)的特定激动剂(配体)。 目的:研究三种脂肽(达普霉素、表面蛋白和多粘菌素)的分子对接,并以此作为药物设计的手段。 方法:用Schrodinger软件进行脂肽与相应配体的分子对接,用RCSB进行配体搜索。一旦识别出配体,它们就是与它们相应的脂肽对接。以对接评分和滑翔能量为参数进行对接试验。 结果:所鉴定的4种配体均与达普霉素连接,而表面蛋白和多粘菌素的配体中,有1/2的配体与脂肽对接。 结论:本文所述脂肽与配体的对接位点及对接特性的了解,可以提供快速、可靠、降低成本的优势。关于化学品和实验以及与使用动物模型筛选药物毒性有关的伦理问题。
关键词: 抗菌肽,脂肽,分子对接,达普霉素,表面素,多粘菌素。
图形摘要
Current Drug Targets
Title:Identification of Novel Ligands for Therapeutic Lipopeptides: Daptomycin, Surfactin and Polymyxin
Volume: 19 Issue: 13
关键词: 抗菌肽,脂肽,分子对接,达普霉素,表面素,多粘菌素。
摘要: Background: Due to increase in antibiotic-resistance among pathogens, there is a need for potent and safe drugs. An alternative to antibiotics is lipopeptides which are produced as a secondary metabolite by many microorganisms. They exhibit broad-spectrum activities against pathogens along with anticancer properties. Among various lipopeptides produced by microorganisms, daptomycin, surfactin, and polymyxin have gained popularity as medicines but their mechanism of action is not described properly. In silico drug design of these lipopeptides becomes a challenge due to their complex structures. In order to initiate a physiological response, specific agonists (ligands) of their receptor (lipopeptide) must be identified.
Objective: The objective of this study was molecular docking of three lipopeptides, daptomycin, surfactin and polymyxin, with their ligands as a means of drug design.
Method: Schrödinger software was used for molecular docking of lipopeptides with their corresponding ligands whereas the ligand search was done using RCSB. Once the ligands were identified, they were docked with their corresponding lipopeptide. Docking score and glide energy were used as the parameters to test docking.
Results: All four of the identified ligands were found to dock with daptomycin, whereas for both surfactin and polymyxin one out of two ligands docked with the lipopeptides.
Conclusion: The knowledge of the docking sites and docking characteristics of the lipopeptide mentioned in the paper with the ligands can provide advantages of high speed and reliability, reduced costs on chemicals and experiments and the ethical issues concerned with the use of animal models for screening of drug toxicity.
Export Options
About this article
Cite this article as:
Identification of Novel Ligands for Therapeutic Lipopeptides: Daptomycin, Surfactin and Polymyxin, Current Drug Targets 2018; 19 (13) . https://dx.doi.org/10.2174/1389450119666171129164932
DOI https://dx.doi.org/10.2174/1389450119666171129164932 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers